| From: |
|
Alison Bunce - Medicines and Healthcare Products Regulatory Agency
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Trusts (England) - Medical Director
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
|
|
|
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Chief Executive
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
| Action category: |
|
Class 2: Action within 48 hours
|
| Title: |
|
DRUG ALERT CLASS 2, ACTION WITHIN 48 HOURS, ALLERGAN PHARMACEUTICALS IRELAND, OZURDEX 700 MICROGRAMS INTRAVITREAL IMPLANT IN APPLICATOR.
|
| Broadcast content: |
|
Recall of a number of batches due to the possibility of contamination with a single loose particle of silicone which may become detached from the needle sleeve during administration of the implant and may be delivered into the eye along with the implant.
Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts We understand that this product is used in the hospital setting and is unlikely to be used in General Practice or Community Pharmacy. Please do not send this communication to Community Pharmacists or to GPs.
|